Stockscreener 앱 받기
3.84
5.19%
-0.21
전일 마감가:
$4.05
열려 있는:
$4.12
하루 거래량:
2.52M
Relative Volume:
1.32
시가총액:
$319.47M
수익:
$14.20M
순이익/손실:
$-49.59M
주가수익비율:
-4.5584
EPS:
-0.8424
순현금흐름:
$-35.25M
1주 성능:
-17.42%
1개월 성능:
-29.02%
6개월 성능:
-33.22%
1년 성능:
+91.04%
1일 변동 폭
$3.75
$4.13
1주일 범위
$3.75
$4.88
52주 변동 폭
$1.70
$7.07
Opus Genetics Inc Stock (IRD) Company Profile
명칭
Opus Genetics Inc
전화
248-681-9815
주소
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
3.84 | 319.47M | 14.20M | -49.59M | -35.25M | -0.8424 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-07-29 | 개시 | TD Cowen | Buy |
| 2026-06-23 | 개시 | RBC Capital Mkts | Outperform |
| 2026-06-04 | 개시 | Guggenheim | Buy |
| 2026-05-21 | 개시 | Leerink Partners | Outperform |
| 2026-04-28 | 개시 | Citizens | Mkt Perform |
| 2026-03-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-03-16 | 개시 | Oppenheimer | Outperform |
| 2026-01-20 | 개시 | BTIG Research | Buy |
| 2025-12-10 | 개시 | B. Riley Securities | Buy |
| 2025-11-25 | 개시 | Piper Sandler | Overweight |
| 2025-10-29 | 개시 | Wedbush | Outperform |
| 2025-10-16 | 개시 | Chardan Capital Markets | Buy |
| 2025-04-11 | 개시 | Craig Hallum | Buy |
| 2024-11-13 | 재개 | H.C. Wainwright | Buy |
모두보기
Opus Genetics Inc 주식(IRD)의 최신 뉴스
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - GlobeNewswire Inc.
Foundation fighting blindness fund sells $2.75m in Opus Genetics stock - Investing.com
Form 4 Opus Genetics Inc For: 2 October By Investing.com - Investing.com Canada
A fund sells shares in Opus Genetics (IRD), leaving a 3.24M-share holding. - Stock Titan
Opus Genetics (IRD) CEO exercises 392K-share warrant in cashless deal - stocktitan.net
Form 8K Opus Genetics Inc For: 11 September By Investing.com - Investing.com Nigeria
Opus Genetics Updates Clinical Data Presentation for OPGx-BEST1 Phase 1/2 Trial - Kalkine Media
Form 8K Opus Genetics Inc For: 11 September By Investing.com - Investing.com Australia
Opus Genetics Gene Therapy OPGx-BEST1 Safe, Shows Improvement in 4 of 5 Patients - Minichart
Opus Genetics Updates OPGx-BEST1 Trial Data and Outlook - TipRanks
Form 8K Opus Genetics Inc For: 11 September By Investing.com - Investing.com Canada
Form 8K Opus Genetics Inc For: 11 September By Investing.com - Investing.com UK
Opus Genetics Inc - Reuters
Opus Genetics CEO George Magrath Executes Warrant for 392,157 Shares via Cashless Exercise - Kalkine Media
Opus Genetics (NASDAQ: IRD) Plans Phase 3 Trial for OPGx-BEST1 in 2027 Following Promising Cohort 1 Results - Kalkine Media
Opus BEST1 and done? Gene therapy scores in rare eye diseases - BioWorld News
Opus Genetics: A Resounding Study Success Merits A Higher Valuation (NASDAQ:IRD) - Seeking Alpha
IRD Maintained by Wedbush -- Price Target Raised to $13.00 - GuruFocus
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $10 to $20 - Moomoo
Chardan Raises Price Target on Opus Genetics to $16 From $13, Keeps Buy Rating - marketscreener.com
Opus Genetics Stock Jumps 32% on Five-Patient Eye-Therapy Data—What IRD Must Prove Next - TechStock²
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Wedbush raises Opus Genetics stock price target on FDA alignment By Investing.com - Investing.com Nigeria
IRD Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
Wedbush raises Opus Genetics stock price target on FDA alignment By Investing.com - Investing.com Australia
Opus Genetics Shares Jump 30% as Low-Dose Gene Therapy Shows Vision Gains in Retinal Disease Trial - finance.biggo.com
Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy TrialSlideshow - Seeking Alpha
Opus Genetics Shares Rise After Reporting Vision Improvement in Phase 1/2 OPGx-BEST1 Trial - marketscreener.com
Wedbush raises Opus Genetics stock price target on FDA alignment By Investing.com - Investing.com South Africa
IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial - Yahoo Finance
IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial - Stocktwits
Wedbush raises Opus Genetics stock price target on FDA alignment By Investing.com - Investing.com India
Wedbush raises Opus Genetics stock price target on FDA alignment By Investing.com - Investing.com Canada
Wedbush raises Opus Genetics stock price target on FDA alignment By Investing.com - Investing.com UK
Wedbush raises Opus Genetics stock price target on FDA alignment - Investing.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
IRD: OPGX-BEST1 gene therapy showed robust safety and efficacy, supporting phase III advancement - TradingView
IRD Reiterates by BTIG -- Price Target Maintained at $12.00 - GuruFocus
Why Opus Genetics (IRD) Stock Is Up Today - quiverquant.com
LifeSci Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Raises Target Price to $20 - Moomoo
Opus Genetics Reports Positive Phase 1/2 Data for Gene Therapy OPGx-BEST1 - Minichart
Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says - Benzinga
IRD: OPGX-BEST1 Phase 1/2 trial showed strong efficacy, safety, and FDA alignment for pivotal development - TradingView
Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data, Targets Potential Phase 3 Dosing in 2027 - Yahoo Finance
IRD: OPGX-BEST1 gene therapy showed robust safety and functional gains, supporting pivotal trial advancement - TradingView
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving High - Benzinga
Opus Genetics Reveals Interim Phase 1/2 BIRD-1 Trial Outcomes for OPGx-BEST1 - Kalkine Media
IRD Stock Jumps As Traders Target Gene Therapy Catalyst - timothysykes.com
IRD Stock Eyes Webcast Catalyst As Gene Therapy Data Nears - StocksToTrade
IRD Maintained by Chardan Capital -- Price Target at $13.00 - GuruFocus
Opus Genetics Inc (IRD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Opus Genetics Inc 주식 (IRD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Magrath George | Chief Executive Officer |
Sep 09 '26 |
Option Exercise |
1.15 |
392,157 |
450,981 |
2,124,026 |
| Gallagher Cam | Director |
Sep 08 '26 |
Option Exercise |
1.15 |
784,314 |
901,961 |
2,800,111 |
| Gagnon Robert E. | Officer |
Sep 03 '26 |
Proposed Sale |
4.45 |
28,000 |
124,600 |
0 |
| Gagnon Robert E. | Chief Financial Officer |
Sep 03 '26 |
Sale |
4.54 |
28,000 |
127,212 |
556,375 |
| Gagnon Robert E. | Officer |
Jul 23 '26 |
Proposed Sale |
3.05 |
7,783 |
23,738 |
0 |
| Magrath George | Officer |
Jul 23 '26 |
Proposed Sale |
3.05 |
9,475 |
28,899 |
0 |
| SCHACHLE JOSEPH K | Officer |
Jul 23 '26 |
Proposed Sale |
2.94 |
4,644 |
13,653 |
0 |
| YERXA BENJAMIN R | Officer |
Jul 23 '26 |
Proposed Sale |
2.97 |
7,429 |
22,064 |
0 |
| YERXA BENJAMIN R | President |
Jul 23 '26 |
Sale |
2.97 |
7,429 |
22,064 |
704,106 |
| SCHACHLE JOSEPH K | Chief Operating Officer |
Jul 23 '26 |
Sale |
2.94 |
4,644 |
13,653 |
291,440 |
4.22%
자본화:
|
볼륨(24시간):